We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Commitments would deliver immediate improvements to the way UK developers publish apps and how they access Apple’s tools.
Learn more about getting started with Self Assessment including registration, tax returns, tax bills and payments.
Learn more about your responsibilities if you’re running a small business including registration, tax returns, record keeping, tax bills and payments.
What the Competition and Markets Authority (CMA) has done, and will do, to promote innovation, investment and growth in UK mobile platforms.
An update from the government on industry-led measures to improve player protections with regards to loot boxes in video games.
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management...
What you must do to get paid for this CSHT action and advice on how to do it.
Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).